Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
50.77
+0.08 (+0.16%)
Streaming Delayed Price
Updated: 9:32 AM EDT, Apr 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
...
22
23
24
25
26
27
28
29
30
...
36
37
Next >
New Data for Genentech’s Ocrevus (ocrelizumab) Show Benefit in Disability Progression and Cognitive Decline in Both Secondary Progressive and Primary Progressive Multiple Sclerosis
April 04, 2022
From
Genentech
Via
Business Wire
SoftBank Loses Vision Fund Leader; Continues To Liquidate Portfolio
↗
April 04, 2022
Ron Fisher looked to depart as the head of SoftBank Group Corp's (OTC: SFTBY) (OTC: SFTBF) Vision Fund and Chair and director of SoftBank Investment Advisors U.S....
Via
Benzinga
Genentech's Ocrevus Shows Benefit In Disability Progression & Cognitive Decline In Multiple Sclerosis
↗
April 04, 2022
Via
Benzinga
FDA Grants Priority Review To Roche's Actemra For Hospitalized COVID-19 Adults
↗
April 04, 2022
Via
Benzinga
Why Are ImmunoGen Shares Trading Lower Today
↗
March 21, 2022
ImmunoGen Inc (NASDAQ: IMGN)
Via
Benzinga
U.S. FDA Grants Priority Review to Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults
April 04, 2022
From
Genentech
Via
Business Wire
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
↗
April 01, 2022
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with...
Via
Benzinga
Roche's Tiragolumab Immunotherapy Flunks In Late-Stage Lung Cancer Trial
↗
March 30, 2022
Roche Holding AG's (OTC: RHHBY) Phase 3 SKYSCRAPER-02 study in extensive-stage small-cell lung cancer (ES-SCLC)
Via
Benzinga
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
↗
March 30, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Genentech Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-Stage Small Cell Lung Cancer
March 30, 2022
From
Genentech
Via
Business Wire
Biotech Funds and ETFs Continue to Lag
↗
March 28, 2022
It’s no secret that market sectors driving inflation are leading the market. With the US economy still strong and the War in Ukraine limiting supply of nat gas and raw materials, producer costs are...
Via
Talk Markets
Drug makers, Scientists Working For Long COVID Treatments: Reuters
↗
March 25, 2022
Researchers and drugmakers, including those who have launched antiviral pills and monoclonal antibodies for COVID-19, are having early discussions about targeting Long COVID,
Via
Benzinga
The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO
↗
March 25, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Flood Helping Ukraine
↗
March 24, 2022
Emerging markets are gaining as mature markets look risky.
Via
Talk Markets
How Rivals Merck, Bristol Myers Benefit From Eli Lilly's FDA Snag
↗
March 24, 2022
The Food and Drug Administration on Thursday rejected a lung cancer drug Eli Lilly tested only in China, but LLY stock inched higher.
Via
Investor's Business Daily
Up On Bad News
↗
March 22, 2022
Despite the plane crash in China, Boeing's stock is up today.
Via
Talk Markets
World Markets News For Friday
↗
March 18, 2022
Buoyant global markets are closing the week and one good performer, Vir Biotech, today gained an impressive 6.09%.
Via
Talk Markets
Roche's Evrysdi Shows Long-Term Efficacy, Safety In Broader Spinal Muscular Atrophy Population
↗
March 16, 2022
Via
Benzinga
Apellis Pharma Nears Breakout As Biotech Plots Its Blockbuster Filing
↗
March 16, 2022
If approved, this would be the company's second drug to hit the U.S. market.
Via
Investor's Business Daily
New Data for Genentech’s Evrysdi (risdiplam) Demonstrate Long-Term Efficacy and Safety in a Broad Population of People With Spinal Muscular Atrophy (SMA)
March 16, 2022
From
Genentech
Via
Business Wire
The OTCQX's Top 10 Experience A Shuffle In February
↗
March 15, 2022
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
↗
March 15, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy
↗
March 15, 2022
Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus...
Via
Benzinga
Hopes For A Peace Accord
↗
March 14, 2022
The winner today was BioNTech up 14.89% on hopes for new sales for the Covid-19 variant.
Via
Talk Markets
Biogen Posts New Updates Across its Spinraza SMA Research Program
↗
March 14, 2022
Biogen Inc (NASDAQ: BIIB) announced new data and updates from its Spinraza (nusinersen) and spinal muscular atrophy (SMA) research program, including the ASCEND, RESPOND and...
Via
Benzinga
Vaccine Stocks BioNTech, Moderna Pop On Fourth Dose — But IBD/TIPP Poll Says Few People Care
↗
March 09, 2022
The IBD/TIPP Poll shows Covid has fallen among Americans' priorities.
Via
Investor's Business Daily
OTC Markets 2021 Annual Data Review Highlights A Record 60% $ Volume Increase
↗
March 07, 2022
Photo by Sophie Bakes on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. The...
Via
Benzinga
The Ruble Is Rubble
↗
March 03, 2022
MSCI says Russian companies are
Via
Talk Markets
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
↗
March 13, 2022
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...
Via
Benzinga
Holiday Over
↗
February 22, 2022
China is busily avoiding taking sides between Ukraine and Russia.
Via
Talk Markets
< Previous
1
2
...
22
23
24
25
26
27
28
29
30
...
36
37
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
